SI2279004T1 - Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina - Google Patents
Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrinaInfo
- Publication number
- SI2279004T1 SI2279004T1 SI200931167T SI200931167T SI2279004T1 SI 2279004 T1 SI2279004 T1 SI 2279004T1 SI 200931167 T SI200931167 T SI 200931167T SI 200931167 T SI200931167 T SI 200931167T SI 2279004 T1 SI2279004 T1 SI 2279004T1
- Authority
- SI
- Slovenia
- Prior art keywords
- biomarkers
- antagonists
- inflammatory disorders
- gastrointestinal inflammatory
- assessing treatment
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70546—Integrin superfamily, e.g. VLAs, leuCAM, GPIIb/GPIIIa, LPAM
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/06—Gastro-intestinal diseases
- G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5411508P | 2008-05-16 | 2008-05-16 | |
PCT/US2009/044375 WO2009140684A2 (en) | 2008-05-16 | 2009-05-18 | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
EP09747765.7A EP2279004B1 (en) | 2008-05-16 | 2009-05-18 | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7integrin antagonists |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2279004T1 true SI2279004T1 (sl) | 2015-05-29 |
Family
ID=41175703
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200931167T SI2279004T1 (sl) | 2008-05-16 | 2009-05-18 | Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina |
Country Status (15)
Country | Link |
---|---|
US (5) | US20100255508A1 (sl) |
EP (1) | EP2279004B1 (sl) |
JP (4) | JP6219556B2 (sl) |
KR (2) | KR101511453B1 (sl) |
CN (1) | CN102124344B (sl) |
AU (1) | AU2009246071B2 (sl) |
BR (1) | BRPI0908665A2 (sl) |
CA (1) | CA2723614C (sl) |
DK (1) | DK2279004T3 (sl) |
ES (1) | ES2533480T3 (sl) |
IL (1) | IL209079A (sl) |
MX (1) | MX2010012368A (sl) |
PL (1) | PL2279004T3 (sl) |
SI (1) | SI2279004T1 (sl) |
WO (1) | WO2009140684A2 (sl) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RS60565B1 (sr) * | 2010-10-25 | 2020-08-31 | Biogen Ma Inc | Postupci za određivanje razlika u aktivnosti alfa-4 integrina putem uspostavljanja korelacije sa razlikama u nivoima svcam i/ili smadcam |
CA2831732C (en) * | 2011-03-31 | 2019-12-31 | Genentech, Inc. | Use of a monoclonal anti-beta7 antibody for treating gastrointestinal inflammatory disorders |
CA2856866C (en) * | 2011-11-23 | 2022-07-12 | Amgen Inc. | Administration of alpha4beta7 hetero-dimer-specific antibody |
EP2642276A1 (en) * | 2012-03-22 | 2013-09-25 | Inoviem Scientific | Method of dynamic spectroscopy under physiological conditions |
ES2738305T3 (es) * | 2012-10-05 | 2020-01-21 | Hoffmann La Roche | Procedimientos para diagnosticar y tratar enfermedades inflamatorias intestinales |
RU2015139147A (ru) * | 2013-02-15 | 2017-03-21 | Персеус Протеомикс Инк. | Гуманизированное антитело к cdh3, его конъюгат с лекарственным средством и их применение |
CA2904095A1 (en) | 2013-03-27 | 2014-10-02 | Genentech, Inc. | Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists |
CN104623637A (zh) | 2013-11-07 | 2015-05-20 | 健能隆医药技术(上海)有限公司 | Il-22二聚体在制备静脉注射药物中的应用 |
AU2015235986B2 (en) * | 2014-03-27 | 2020-12-03 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
CA2969326A1 (en) * | 2014-12-02 | 2016-06-09 | Nestec S.A. | Methods for establishing a vedolizumab dosing regimen to treat patients with irritable bowel disease |
CN113209289A (zh) * | 2015-02-26 | 2021-08-06 | 豪夫迈·罗氏有限公司 | 治疗Crohn病的整联蛋白β7拮抗剂和方法 |
US10295527B2 (en) | 2016-03-14 | 2019-05-21 | Bruce Yacyshyn | Process and system for predicting responders and non-responders to mesalamine treatment of ulcerative colitis |
US11946927B2 (en) | 2016-03-14 | 2024-04-02 | Musidora Biotechnology Llc | Process and system for identifying individuals having a high risk of inflammatory bowel disease and a method of treatment |
EP3442562B1 (en) | 2016-04-15 | 2022-09-21 | Evive Biotechnology (Shanghai) Ltd | An il-22 dimer for use in treating necrotizing enterocolitis |
CN110072551B (zh) * | 2016-12-14 | 2023-05-23 | 比奥拉治疗股份有限公司 | 使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病 |
US20210147547A1 (en) * | 2018-04-13 | 2021-05-20 | Novartis Ag | Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof |
IL300133A (en) | 2020-07-31 | 2023-03-01 | Genentech Inc | Anti-integrin antibody compositions in cell 7 and devices |
TW202330613A (zh) | 2021-11-12 | 2023-08-01 | 美商建南德克公司 | 使用整聯蛋白β7拮抗劑治療克隆氏病之方法 |
Family Cites Families (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4A (en) * | 1836-08-10 | Stock | ||
US4151042A (en) * | 1977-03-31 | 1979-04-24 | Takeda Chemical Industries, Ltd. | Method for producing maytansinol and its derivatives |
US4137230A (en) * | 1977-11-14 | 1979-01-30 | Takeda Chemical Industries, Ltd. | Method for the production of maytansinoids |
FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
US4265814A (en) * | 1978-03-24 | 1981-05-05 | Takeda Chemical Industries | Matansinol 3-n-hexadecanoate |
US4307016A (en) * | 1978-03-24 | 1981-12-22 | Takeda Chemical Industries, Ltd. | Demethyl maytansinoids |
JPS5562090A (en) * | 1978-10-27 | 1980-05-10 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS5566585A (en) * | 1978-11-14 | 1980-05-20 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164687A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4256746A (en) * | 1978-11-14 | 1981-03-17 | Takeda Chemical Industries | Dechloromaytansinoids, their pharmaceutical compositions and method of use |
US4256833A (en) | 1979-01-08 | 1981-03-17 | Majid Ali | Enzyme immunoassay for allergic disorders |
JPS55102583A (en) * | 1979-01-31 | 1980-08-05 | Takeda Chem Ind Ltd | 20-acyloxy-20-demethylmaytansinoid compound |
JPS55164685A (en) * | 1979-06-08 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
JPS55164686A (en) * | 1979-06-11 | 1980-12-22 | Takeda Chem Ind Ltd | Novel maytansinoid compound and its preparation |
US4309428A (en) * | 1979-07-30 | 1982-01-05 | Takeda Chemical Industries, Ltd. | Maytansinoids |
JPS5645483A (en) * | 1979-09-19 | 1981-04-25 | Takeda Chem Ind Ltd | C-15003phm and its preparation |
JPS5645485A (en) * | 1979-09-21 | 1981-04-25 | Takeda Chem Ind Ltd | Production of c-15003pnd |
EP0028683A1 (en) * | 1979-09-21 | 1981-05-20 | Takeda Chemical Industries, Ltd. | Antibiotic C-15003 PHO and production thereof |
WO1982001188A1 (en) * | 1980-10-08 | 1982-04-15 | Takeda Chemical Industries Ltd | 4,5-deoxymaytansinoide compounds and process for preparing same |
US4450254A (en) * | 1980-11-03 | 1984-05-22 | Standard Oil Company | Impact improvement of high nitrile resins |
US4315929A (en) * | 1981-01-27 | 1982-02-16 | The United States Of America As Represented By The Secretary Of Agriculture | Method of controlling the European corn borer with trewiasine |
US4313946A (en) * | 1981-01-27 | 1982-02-02 | The United States Of America As Represented By The Secretary Of Agriculture | Chemotherapeutically active maytansinoids from Trewia nudiflora |
US4563304A (en) * | 1981-02-27 | 1986-01-07 | Pharmacia Fine Chemicals Ab | Pyridine compounds modifying proteins, polypeptides or polysaccharides |
JPS57192389A (en) * | 1981-05-20 | 1982-11-26 | Takeda Chem Ind Ltd | Novel maytansinoid |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
US4816567A (en) * | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
DD266710A3 (de) | 1983-06-06 | 1989-04-12 | Ve Forschungszentrum Biotechnologie | Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4970198A (en) * | 1985-10-17 | 1990-11-13 | American Cyanamid Company | Antitumor antibiotics (LL-E33288 complex) |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5079233A (en) * | 1987-01-30 | 1992-01-07 | American Cyanamid Company | N-acyl derivatives of the LL-E33288 antitumor antibiotics, composition and methods for using the same |
AU600575B2 (en) * | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US4975278A (en) * | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5053394A (en) * | 1988-09-21 | 1991-10-01 | American Cyanamid Company | Targeted forms of methyltrithio antitumor agents |
US5606040A (en) * | 1987-10-30 | 1997-02-25 | American Cyanamid Company | Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
RO110397B1 (ro) | 1989-03-21 | 1996-01-30 | Immune Response Corp San Diego | Vaccin pentru prevenirea sau tratarea unor boli care rezulta din raspunsuri patogene, prin populatii de celule t specifice, procedeu de obtinere si metode de diagnostic si tratament cu acesta |
EP0479909B1 (en) | 1989-06-29 | 1996-10-30 | Medarex, Inc. | Bispecific reagents for aids therapy |
ATE161850T1 (de) | 1989-07-19 | 1998-01-15 | Connetics Corp | T-zell-rezeptor-peptide als heilmittel für autoimmune und bösartige krankheiten |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5427908A (en) * | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
GB9015198D0 (en) * | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
US6172197B1 (en) * | 1991-07-10 | 2001-01-09 | Medical Research Council | Methods for producing members of specific binding pairs |
ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
ATE164395T1 (de) * | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
IE921169A1 (en) * | 1991-04-10 | 1992-10-21 | Scripps Research Inst | Heterodimeric receptor libraries using phagemids |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
US5733743A (en) * | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
AU690528B2 (en) * | 1992-12-04 | 1998-04-30 | Medical Research Council | Multivalent and multispecific binding proteins, their manufacture and use |
US5534615A (en) | 1994-04-25 | 1996-07-09 | Genentech, Inc. | Cardiac hypertrophy factor and uses therefor |
US5610281A (en) * | 1994-05-03 | 1997-03-11 | Brigham & Women's Hospital, Inc. | Antibodies for modulating heterotypic E-cadherin interactions with human T lymphocytes |
US5773001A (en) * | 1994-06-03 | 1998-06-30 | American Cyanamid Company | Conjugates of methyltrithio antitumor agents and intermediates for their synthesis |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US6551593B1 (en) * | 1995-02-10 | 2003-04-22 | Millennium Pharmaceuticals, Inc. | Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam |
ES2290955T3 (es) * | 1995-02-10 | 2008-02-16 | Millennium Pharmaceuticals, Inc. | Adresinas vasculares de mucosas y sus usos. |
US5731168A (en) * | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5712374A (en) * | 1995-06-07 | 1998-01-27 | American Cyanamid Company | Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates |
US5714586A (en) * | 1995-06-07 | 1998-02-03 | American Cyanamid Company | Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates |
DE19544393A1 (de) | 1995-11-15 | 1997-05-22 | Hoechst Schering Agrevo Gmbh | Synergistische herbizide Mischungen |
US5922570A (en) * | 1996-01-05 | 1999-07-13 | Icos Corporation | Cytoplasmic Modulators of Integrin Binding/Signalling |
WO1997033551A2 (en) | 1996-03-15 | 1997-09-18 | Millennium Pharmaceuticals | Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation |
US20010046496A1 (en) * | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
AP2006003689A0 (en) * | 2004-01-09 | 2006-08-31 | Pfizer | Antibodies to MAdCAM |
PL1784426T3 (pl) * | 2004-09-03 | 2012-04-30 | Genentech Inc | Humanizowani antagoniści anty-beta7 i ich zastosowania |
EP1805210A4 (en) * | 2004-09-09 | 2007-10-24 | Auckland Uniservices Ltd | NOVEL PEPTIDES AND METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASE |
US20100028450A1 (en) * | 2006-01-25 | 2010-02-04 | The Board Of Trustees Of The University Of Illinoi S | Tolerogenic biodegradable artificial antigen presenting system |
EP1996936B1 (en) * | 2006-03-20 | 2010-08-04 | St Vincent's Hospital Sydney Limited | A method for detecting antigen-specific or mitogen-activated t cells |
US10982250B2 (en) * | 2006-09-18 | 2021-04-20 | Genentech, Inc. | Methods of protein production |
JP2007302676A (ja) * | 2007-05-29 | 2007-11-22 | Genentech Inc | ヒト化抗β7アンタゴニストおよびその使用 |
US20090004189A1 (en) * | 2007-06-18 | 2009-01-01 | Genentech, Inc. | Biological markers predictive of rheumatoid arthritis response to b-cell antagonists |
AU2015235986B2 (en) * | 2014-03-27 | 2020-12-03 | Genentech, Inc. | Methods for diagnosing and treating inflammatory bowel disease |
-
2009
- 2009-05-18 AU AU2009246071A patent/AU2009246071B2/en active Active
- 2009-05-18 EP EP09747765.7A patent/EP2279004B1/en active Active
- 2009-05-18 SI SI200931167T patent/SI2279004T1/sl unknown
- 2009-05-18 BR BRPI0908665-0A patent/BRPI0908665A2/pt not_active IP Right Cessation
- 2009-05-18 ES ES09747765.7T patent/ES2533480T3/es active Active
- 2009-05-18 CN CN200980127645.9A patent/CN102124344B/zh active Active
- 2009-05-18 KR KR1020137005417A patent/KR101511453B1/ko active IP Right Grant
- 2009-05-18 DK DK09747765.7T patent/DK2279004T3/en active
- 2009-05-18 WO PCT/US2009/044375 patent/WO2009140684A2/en active Application Filing
- 2009-05-18 JP JP2011509793A patent/JP6219556B2/ja active Active
- 2009-05-18 MX MX2010012368A patent/MX2010012368A/es active IP Right Grant
- 2009-05-18 KR KR1020107028233A patent/KR101361905B1/ko active IP Right Grant
- 2009-05-18 PL PL09747765T patent/PL2279004T3/pl unknown
- 2009-05-18 CA CA2723614A patent/CA2723614C/en active Active
- 2009-05-18 US US12/467,402 patent/US20100255508A1/en not_active Abandoned
-
2010
- 2010-11-02 IL IL209079A patent/IL209079A/en active IP Right Grant
-
2011
- 2011-09-16 US US13/234,976 patent/US20130109032A1/en not_active Abandoned
-
2013
- 2013-08-19 JP JP2013169404A patent/JP2013253987A/ja active Pending
-
2016
- 2016-02-29 JP JP2016037442A patent/JP2016136963A/ja not_active Withdrawn
- 2016-05-06 US US15/148,573 patent/US20170102393A1/en not_active Abandoned
-
2017
- 2017-07-18 JP JP2017139448A patent/JP2017223685A/ja active Pending
-
2018
- 2018-11-20 US US16/196,687 patent/US20190310266A1/en not_active Abandoned
-
2021
- 2021-12-16 US US17/552,486 patent/US20220349903A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2011521236A (ja) | 2011-07-21 |
US20170102393A1 (en) | 2017-04-13 |
AU2009246071B2 (en) | 2013-10-03 |
KR101361905B1 (ko) | 2014-02-21 |
US20190310266A1 (en) | 2019-10-10 |
US20220349903A1 (en) | 2022-11-03 |
IL209079A0 (en) | 2011-01-31 |
MX2010012368A (es) | 2010-12-06 |
WO2009140684A2 (en) | 2009-11-19 |
US20100255508A1 (en) | 2010-10-07 |
JP6219556B2 (ja) | 2017-10-25 |
AU2009246071A1 (en) | 2009-11-19 |
KR20110018365A (ko) | 2011-02-23 |
JP2016136963A (ja) | 2016-08-04 |
KR101511453B1 (ko) | 2015-04-10 |
CA2723614C (en) | 2015-07-14 |
ES2533480T3 (es) | 2015-04-10 |
CA2723614A1 (en) | 2009-11-19 |
CN102124344A (zh) | 2011-07-13 |
JP2013253987A (ja) | 2013-12-19 |
EP2279004B1 (en) | 2015-01-14 |
CN102124344B (zh) | 2015-04-01 |
BRPI0908665A2 (pt) | 2020-08-18 |
DK2279004T3 (en) | 2015-02-02 |
PL2279004T3 (pl) | 2015-06-30 |
WO2009140684A3 (en) | 2011-01-13 |
IL209079A (en) | 2016-05-31 |
US20130109032A1 (en) | 2013-05-02 |
KR20130038946A (ko) | 2013-04-18 |
JP2017223685A (ja) | 2017-12-21 |
EP2279004A2 (en) | 2011-02-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SI2279004T1 (sl) | Uporaba biomarkerjev za ocenjevanje zdravljenja gastrointestinalnih vnetnih motenj z antagonisti beta7 integrina | |
EP2272044A4 (en) | INFLAMMATION BIOMARKERS FOR MONITORING DEPRESSION DISORDERS | |
ZA201009030B (en) | Methods of treating inflammatory colon disease | |
HK1218442A1 (zh) | 生物標誌物用於評估用β 整聯蛋白拮抗劑治療胃腸炎性病症的用途 | |
IL216720A (en) | Biological markers for assessing kidney disease | |
HK1254807A1 (zh) | 用於評估肝病變的方法 | |
EP2347256A4 (en) | USE AND IDENTIFICATION OF BIOMARKERS FOR GASTROINTESTINAL DISEASES | |
EP2405805A4 (en) | METHODS AND APPARATUS FOR ASSESSING PHYSIOLOGICAL CONDITIONS | |
EP2443461A4 (en) | BIOMARKER ASSAY FOR NERVES | |
GB2509478B (en) | Intra-block memory wear leveling | |
IL212622A0 (en) | Biomarkers for assessing atherosclerotic potential | |
EP2453738A4 (en) | METHODS OF EVALUATING THE ISSUE OF AN EMBRYO | |
EP2337866A4 (en) | MULTIDIMENSIONAL HUMAN BIOMARKER HYPERESPACE MAPPING FOR DEPRESSIVE DISORDERS | |
ZA201105056B (en) | 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2 | |
IL215895A0 (en) | Isoxazole-thiazole derivatives as gaba a receptor inverse agonists for use in the treatment of cognitive disorders | |
GB0823315D0 (en) | Fluorescent Probes | |
EP2342355A4 (en) | METHODS OF USING BIOMARKERS | |
ZA201105184B (en) | Biomarker | |
GB0812759D0 (en) | Inspection probe | |
EP2555791A4 (en) | METHOD FOR THE TREATMENT OF DISEASES OF THE STOMACH DARM TRAKTS BY A GLP-1 AGONIST | |
EP2340436A4 (en) | METHODS OF DIAGNOSING AND ASSESSING AUTOIMMUNE DISORDERS | |
IL208189A0 (en) | Use of defensins against meningitis | |
ZA201008471B (en) | Biomarker for selecting patients and related methods | |
GB0819446D0 (en) | Treatment of inflammatory disorders | |
GB0704515D0 (en) | Diagnosing psychotic disorders |